Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cevostamab + pomalidomide + dexamethasone after prior BCMA CAR-T for multiple myeloma
2026-525736-42-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Sep 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cevostamab, pomalidomide and dexamethasone in multiple myeloma (MM), sponsored by Roche. Primary endpoint: Overall response rate. Planned start Sep 2026; status: authorised.
02
Drugs
cevostamabpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2026-525736-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525736-42-00.